-
公开(公告)号:US20220233706A1
公开(公告)日:2022-07-28
申请号:US17531199
申请日:2021-11-19
发明人: Mahendra Persaud Deonarain , Gokhan Yahioglu , Ioanna Stamati , Savvas Saouros , Prashant Bhimrao Kapadnis
IPC分类号: A61K47/68
摘要: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
-
公开(公告)号:US11202837B2
公开(公告)日:2021-12-21
申请号:US15513393
申请日:2015-09-25
发明人: Mahendra Persaud Deonarain , Gokhan Yahioglu , Ioanna Stamati , Savvas Saouros , Prashant Bhimrao Kapadnis
摘要: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
-
公开(公告)号:US20170360951A1
公开(公告)日:2017-12-21
申请号:US15513393
申请日:2015-09-25
发明人: Mahendra Persaud Deonarain , Gokhan Yahioglu , Ioanna Stamati , Savvas Saouros , Prashant Bhimrao Kapadnis
CPC分类号: A61K47/6803 , A61K47/00 , A61K47/6809 , A61K47/6855 , C07K16/00 , C07K2317/92
摘要: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
-
-